BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2043 related articles for article (PubMed ID: 33508920)

  • 1. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
    Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
    BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
    Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study.
    Chen L; Zhang C; Yao Z; Cui M; Xing J; Yang H; Zhang N; Liu M; Xu K; Tan F; Li Y; Jiang B; Su X
    BMC Cancer; 2021 Aug; 21(1):974. PubMed ID: 34461860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.
    Feng D; Leong M; Li T; Chen L; Li T
    World J Surg Oncol; 2015 Jan; 13():11. PubMed ID: 25634099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical value of superior mesenteric vein (No.14v) lymph node dissection in D2 gastrectomy for locally advanced distal gastric cancer].
    Lu W; Zeng X; Li N; Liu H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1136-1141. PubMed ID: 30370512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
    Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
    Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification.
    Wei J; Yao T; Wang Y; Li L; Pan C; Zhang N
    Clin Transl Oncol; 2019 Feb; 21(2):232-238. PubMed ID: 29968135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
    Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
    Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study.
    Zheng S; Zhou Y; Sun Y; Wang Z; Lu Y
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):819-827. PubMed ID: 31388724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma.
    Honma Y; Yamada Y; Terazawa T; Takashima A; Iwasa S; Kato K; Hamaguchi T; Shimada Y; Ohashi M; Morita S; Fukagawa T; Machida N; Katai H
    Surg Today; 2016 Sep; 46(9):1076-82. PubMed ID: 26563224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
    Peng L; Yang W; Zhang Z; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of SOX and CAPOX in patients with advanced gastric cancer after laparoscopic D2 gastrectomy: A randomized controlled trial.
    Liu X; Yan Y; Lu L; Liu Y; Ma J; Wang X; Wang D; Liu B; Liu Z; Zhou X; Cui H; Zhao Z; Li C; Liu J; Li W; Huang QX; Zhao Q; Liu T; Fu W
    Cancer Med; 2024 Jun; 13(11):e7326. PubMed ID: 38826114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
    Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.
    Zhao Q; Lian C; Huo Z; Li M; Liu Y; Fan L; Tan B; Zhao X; Zhang Z; Wang D; Liu Y; Guo H; Yang P; Tian Y; Li Y
    Cancer Med; 2020 Aug; 9(16):5731-5745. PubMed ID: 32583567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
    Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
    Tsuburaya A; Mizusawa J; Tanaka Y; Fukushima N; Nashimoto A; Sasako M;
    Br J Surg; 2014 May; 101(6):653-60. PubMed ID: 24668391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
    Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
    Cheng X; Yu S; Wang Y; Cui Y; Li W; Yu Y; Tang C; Jiang H; Ji Y; Sun Y; Wang X; Shen Z; Liu F; Liu TS
    Gastric Cancer; 2019 May; 22(3):587-597. PubMed ID: 30426294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 103.